Janux Therapeutics Inc (NASDAQ: JANX) kicked off on Monday, up 9.84% from the previous trading day, before settling in for the closing price of $24.9. Over the past 52 weeks, JANX has traded in a range of $21.73-$71.71.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -67.90%. While this was happening, its average annual earnings per share was recorded -76.83%. With a float of $54.31 million, this company’s outstanding shares have now reached $59.30 million.
Janux Therapeutics Inc (JANX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Janux Therapeutics Inc is 9.62%, while institutional ownership is 106.31%. The most recent insider transaction that took place on May 01 ’25, was worth 106,745. In this transaction Chief Business Officer of this company sold 3,333 shares at a rate of $32.03, taking the stock ownership to the 82,139 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 3,333 for $33.20, making the entire transaction worth $110,656.
Janux Therapeutics Inc (JANX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.51 earnings per share (EPS), lower than consensus estimate (set at -0.36) by -0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -76.83% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Take a look at Janux Therapeutics Inc’s (JANX) current performance indicators. Last quarter, stock had a quick ratio of 47.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3735.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -0.61 in the next quarter and is forecasted to reach -3.01 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
The latest stats from [Janux Therapeutics Inc, JANX] show that its last 5-days average volume of 0.86 million was inferior to 0.91 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 26.59%.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 76.36%, which indicates a significant increase from 73.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.68 in the past 14 days, which was higher than the 1.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.40, while its 200-day Moving Average is $28.34. Now, the first resistance to watch is $28.43. This is followed by the second major resistance level at $29.51. The third major resistance level sits at $31.06. If the price goes on to break the first support level at $25.81, it is likely to go to the next support level at $24.26. Assuming the price breaks the second support level, the third support level stands at $23.18.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
The company with the Market Capitalisation of 1.64 billion has total of 60,094K Shares Outstanding. Its annual sales at the moment are 10,590 K in contrast with the sum of -68,990 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -33,860 K.
